# Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

> **NCT02979639** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 404 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)

## Key facts

- **NCT ID:** NCT02979639
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-16
- **Primary completion:** 2017-04-12
- **Final completion:** 2018-05-24
- **Target enrollment:** 404 (ACTUAL)
- **Last updated:** 2019-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02979639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02979639, "Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02979639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*